Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas.

Schiff D, Purow BW.

Nat Rev Neurol. 2009 Jun;5(6):303-4. doi: 10.1038/nrneurol.2009.57.

PMID:
19498431
2.

[IDH1/2 mutations in gliomas].

Nobusawa S, Yokoo H.

Brain Nerve. 2011 Dec;63(12):1378-86. Review. Japanese.

PMID:
22147457
3.

Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas.

Yu L, Qi ST, Li ZY.

Chin Med J (Engl). 2010 Dec;123(24):3697-705. Review.

PMID:
22166653
4.

Isocitrate dehydrogenase 1 and 2 mutations in gliomas.

Megova M, Drabek J, Koudelakova V, Trojanec R, Kalita O, Hajduch M.

J Neurosci Res. 2014 Dec;92(12):1611-20. doi: 10.1002/jnr.23456. Epub 2014 Jul 31. Review.

PMID:
25078896
5.

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.

Ohba S, Hirose Y.

Neurol Med Chir (Tokyo). 2016;56(4):170-9. doi: 10.2176/nmc.ra.2015-0322. Epub 2016 Mar 10. Review.

6.

IDH1 and IDH2 mutations in gliomas.

Cohen AL, Holmen SL, Colman H.

Curr Neurol Neurosci Rep. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. Review.

7.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

8.

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.

Weller M, Wick W, von Deimling A.

Glia. 2011 Aug;59(8):1200-4. doi: 10.1002/glia.21130. Epub 2011 Feb 3. Review.

PMID:
21294161
9.

Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.

Hodges TR, Choi BD, Bigner DD, Yan H, Sampson JH.

J Neurosurg. 2013 Jun;118(6):1176-80. doi: 10.3171/2013.3.JNS122282. Epub 2013 Apr 12. Review.

10.

Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?

Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ.

Lancet Oncol. 2011 Jan;12(1):83-91. doi: 10.1016/S1470-2045(10)70053-X. Epub 2010 Jul 7. Review.

PMID:
20615753
11.

New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.

Shibahara I, Sonoda Y, Kanamori M, Saito R, Kumabe T, Tominaga T.

Brain Tumor Pathol. 2011 Jul;28(3):203-8. doi: 10.1007/s10014-011-0050-4. Epub 2011 Jul 7. Review.

PMID:
21735252
12.

Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?

Singh A, Gurav M, Dhanavade S, Shetty O, Epari S.

Neuropathology. 2017 Dec;37(6):582-585. doi: 10.1111/neup.12401. Epub 2017 Aug 7.

PMID:
28782849
13.

IDH mutations in human glioma.

Kim W, Liau LM.

Neurosurg Clin N Am. 2012 Jul;23(3):471-80. doi: 10.1016/j.nec.2012.04.009. Epub 2012 May 31. Review.

14.

Molecular pathogenesis of IDH mutations in gliomas.

Ichimura K.

Brain Tumor Pathol. 2012 Jul;29(3):131-9. doi: 10.1007/s10014-012-0090-4. Epub 2012 Mar 8. Review.

PMID:
22399191
15.

Glioma-derived mutations in IDH: from mechanism to potential therapy.

Fu Y, Huang R, Du J, Yang R, An N, Liang A.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27. Review.

PMID:
20510884
16.

Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.

Li MY, Wang YY, Cai JQ, Zhang CB, Wang KY, Cheng W, Liu YW, Zhang W, Jiang T.

PLoS One. 2015 Jun 26;10(6):e0130872. doi: 10.1371/journal.pone.0130872. eCollection 2015.

17.

Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.

Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H.

Neurosurg Focus. 2015 Mar;38(3):E2. doi: 10.3171/2015.1.FOCUS14745. Review.

PMID:
25727224
18.

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y.

Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.

19.

Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Gozé C, Blonski M, Le Maistre G, Bauchet L, Dezamis E, Page P, Varlet P, Capelle L, Devaux B, Taillandier L, Duffau H, Pallud J.

Neuro Oncol. 2014 Aug;16(8):1100-9. doi: 10.1093/neuonc/nou085. Epub 2014 May 20.

20.

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.

Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ.

Acta Neuropathol Commun. 2015 Dec 23;3:88. doi: 10.1186/s40478-015-0265-4.

Supplemental Content

Support Center